News | FFR Technologies | August 29, 2018

European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines

iFR-guided strategy now deemed beneficial in the assessment of the functional significance of intermediate coronary stenosis

European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines

August 29, 2018 — Philips announced that the European Society of Cardiology (ESC) has incorporated instantaneous wave-free ratio (iFR) into its updated revascularization guidelines. The new guidelines have provided the highest recommendation (class I A) for iFR alongside fractional flow reserve (FFR) for the objective assessment of the hemodynamic relevance of coronary lesions. In 2017, the DEFINE-FLAIR and iFR Swedeheart studies, the largest randomized coronary physiology outcome studies published to date, showcased iFR as a non-inferior method to FFR during risk stratification in coronary stenosis. iFR is a pressure-derived index unique to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages to identify the appropriate therapy for each patient.

Ischemic heart disease (IHD) causes the highest rate of disability and death compared to any other illness in the world and also incurs the greatest economic costs. Of the approximately 17.7 million people who died from cardiovascular diseases globally in 2015, a total of 7.4 million were a result of coronary heart disease [1]. Philips began offering iFR technology as an alternative to FFR in 2013 in Europe and 2014 in the U.S. The technology offers a procedure that provides functional measurement while reducing patient discomfort by 90 percent, reducing costs by approximately 10 percent per patient over a one-year average and reducing time spent in the cath lab by 10 percent, according to Philips.

Click here to read the full updated ESC revascularization guidelines.

For more information: www.usa.philips.com/healthcare

 

Reference

[1] Cardiovascular diseases (CVDs). (n.d.). Retrieved from http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

Related iFR Content

Updated SCAI Expert Consensus Says Either FFR, iFR Can Be Used

Easier to Use iFR Equal to Outcomes of FFR in Coronary Lesion Evaluation

VIDEO: iFR Found More Cost Effective Over Standard FFR

VIDEO: iFR Equal to FFR Outcomes in Coronary Lesion Evaluation

Related Content

Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
Overlay Init